Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Resident memory T cells are a cellular reservoir for HIV in the cervical mucosa.

Cantero-Pérez J, Grau-Expósito J, Serra-Peinado C, Rosero DA, Luque-Ballesteros L, Astorga-Gamaza A, Castellví J, Sanhueza T, Tapia G, Lloveras B, Fernández MA, Prado JG, Solé-Sedeno JM, Tarrats A, Lecumberri C, Mañalich-Barrachina L, Centeno-Mediavilla C, Falcó V, Buzon MJ, Genescà M.

Nat Commun. 2019 Oct 18;10(1):4739. doi: 10.1038/s41467-019-12732-2.

2.

Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations.

Grau-Expósito J, Luque-Ballesteros L, Navarro J, Curran A, Burgos J, Ribera E, Torrella A, Planas B, Badía R, Martin-Castillo M, Fernández-Sojo J, Genescà M, Falcó V, Buzon MJ.

PLoS Pathog. 2019 Aug 19;15(8):e1007991. doi: 10.1371/journal.ppat.1007991. eCollection 2019 Aug.

3.

Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab.

Serra-Peinado C, Grau-Expósito J, Luque-Ballesteros L, Astorga-Gamaza A, Navarro J, Gallego-Rodriguez J, Martin M, Curran A, Burgos J, Ribera E, Raventós B, Willekens R, Torrella A, Planas B, Badía R, Garcia F, Castellví J, Genescà M, Falcó V, Buzon MJ.

Nat Commun. 2019 Aug 16;10(1):3705. doi: 10.1038/s41467-019-11556-4.

4.

Dendritic Cells From the Cervical Mucosa Capture and Transfer HIV-1 via Siglec-1.

Perez-Zsolt D, Cantero-Pérez J, Erkizia I, Benet S, Pino M, Serra-Peinado C, Hernández-Gallego A, Castellví J, Tapia G, Arnau-Saz V, Garrido J, Tarrats A, Buzón MJ, Martinez-Picado J, Izquierdo-Useros N, Genescà M.

Front Immunol. 2019 Apr 30;10:825. doi: 10.3389/fimmu.2019.00825. eCollection 2019.

5.

Peering into the HIV reservoir.

García M, Buzón MJ, Benito JM, Rallón N.

Rev Med Virol. 2018 Jul;28(4):e1981. doi: 10.1002/rmv.1981. Epub 2018 May 9. Review.

6.

CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells.

Abdel-Mohsen M, Kuri-Cervantes L, Grau-Exposito J, Spivak AM, Nell RA, Tomescu C, Vadrevu SK, Giron LB, Serra-Peinado C, Genescà M, Castellví J, Wu G, Del Rio Estrada PM, González-Navarro M, Lynn K, King CT, Vemula S, Cox K, Wan Y, Li Q, Mounzer K, Kostman J, Frank I, Paiardini M, Hazuda D, Reyes-Terán G, Richman D, Howell B, Tebas P, Martinez-Picado J, Planelles V, Buzon MJ, Betts MR, Montaner LJ.

Sci Transl Med. 2018 Apr 18;10(437). pii: eaar6759. doi: 10.1126/scitranslmed.aar6759.

7.

Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence.

Martinez-Picado J, Zurakowski R, Buzón MJ, Stevenson M.

Retrovirology. 2018 Jan 30;15(1):15. doi: 10.1186/s12977-018-0398-1. Review.

8.

A Novel Single-Cell FISH-Flow Assay Identifies Effector Memory CD4+ T cells as a Major Niche for HIV-1 Transcription in HIV-Infected Patients.

Grau-Expósito J, Serra-Peinado C, Miguel L, Navarro J, Curran A, Burgos J, Ocaña I, Ribera E, Torrella A, Planas B, Badía R, Castellví J, Falcó V, Crespo M, Buzon MJ.

mBio. 2017 Jul 11;8(4). pii: e00876-17. doi: 10.1128/mBio.00876-17.

9.

Lack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART.

Puertas MC, Noguera-Julian M, Massanella M, Pou C, Buzon MJ, Clotet B, Stevenson M, Paredes R, Blanco J, Martinez-Picado J.

Retrovirology. 2016 Aug 2;13(1):51. doi: 10.1186/s12977-016-0282-9.

10.

A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes.

Jones RB, Mueller S, O'Connor R, Rimpel K, Sloan DD, Karel D, Wong HC, Jeng EK, Thomas AS, Whitney JB, Lim SY, Kovacs C, Benko E, Karandish S, Huang SH, Buzon MJ, Lichterfeld M, Irrinki A, Murry JP, Tsai A, Yu H, Geleziunas R, Trocha A, Ostrowski MA, Irvine DJ, Walker BD.

PLoS Pathog. 2016 Apr 15;12(4):e1005545. doi: 10.1371/journal.ppat.1005545. eCollection 2016 Apr.

11.

Correction: Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth.

Kiselinova M, De Spiegelaere W, Buzon MJ, Malatinkova E, Lichterfeld M, Vandekerckhove L.

PLoS Pathog. 2016 Mar 22;12(3):e1005532. doi: 10.1371/journal.ppat.1005532. eCollection 2016 Mar. No abstract available.

12.

Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth.

Kiselinova M, De Spiegelaere W, Buzon MJ, Malatinkova E, Lichterfeld M, Vandekerckhove L.

PLoS Pathog. 2016 Mar 3;12(3):e1005472. doi: 10.1371/journal.ppat.1005472. eCollection 2016 Mar. Erratum in: PLoS Pathog. 2016 Mar;12(3):e1005532.

13.

Transcriptional Changes in CD8(+) T Cells During Antiretroviral Therapy Intensified With Raltegravir.

Ouyang Z, Buzon MJ, Zheng L, Sun H, Yu XG, Bosch RJ, Mellors JW, Eron JJ, Gandhi RT, Lichterfeld M.

Open Forum Infect Dis. 2015 Apr 1;2(2):ofv045. doi: 10.1093/ofid/ofv045. eCollection 2015 Apr.

14.

Potent Cell-Intrinsic Immune Responses in Dendritic Cells Facilitate HIV-1-Specific T Cell Immunity in HIV-1 Elite Controllers.

Martin-Gayo E, Buzon MJ, Ouyang Z, Hickman T, Cronin J, Pimenova D, Walker BD, Lichterfeld M, Yu XG.

PLoS Pathog. 2015 Jun 11;11(6):e1004930. doi: 10.1371/journal.ppat.1004930. eCollection 2015 Jun.

15.

Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals.

Massanella M, Ouchi D, Marfil S, Llibre JM, Puertas MC, Buzón MJ, Richman DD, Orna E, Stevenson M, Gatell JM, Domingo P, Negredo E, Martinez-Picado J, Clotet B, Blanco J.

PLoS One. 2014 Dec 2;9(12):e114142. doi: 10.1371/journal.pone.0114142. eCollection 2014.

16.

Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells.

Buzon MJ, Martin-Gayo E, Pereyra F, Ouyang Z, Sun H, Li JZ, Piovoso M, Shaw A, Dalmau J, Zangger N, Martinez-Picado J, Zurakowski R, Yu XG, Telenti A, Walker BD, Rosenberg ES, Lichterfeld M.

J Virol. 2014 Sep 1;88(17):10056-65. doi: 10.1128/JVI.01046-14. Epub 2014 Jun 25.

17.

A cell-intrinsic inhibitor of HIV-1 reverse transcription in CD4(+) T cells from elite controllers.

Leng J, Ho HP, Buzon MJ, Pereyra F, Walker BD, Yu XG, Chang EJ, Lichterfeld M.

Cell Host Microbe. 2014 Jun 11;15(6):717-728. doi: 10.1016/j.chom.2014.05.011.

18.

HIV-1 persistence in CD4+ T cells with stem cell-like properties.

Buzon MJ, Sun H, Li C, Shaw A, Seiss K, Ouyang Z, Martin-Gayo E, Leng J, Henrich TJ, Li JZ, Pereyra F, Zurakowski R, Walker BD, Rosenberg ES, Yu XG, Lichterfeld M.

Nat Med. 2014 Feb;20(2):139-42. doi: 10.1038/nm.3445. Epub 2014 Jan 12.

19.

Hepatitis C therapy with interferon-α and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C virus-coinfected patients.

Sun H, Buzon MJ, Shaw A, Berg RK, Yu XG, Ferrando-Martinez S, Leal M, Ruiz-Mateos E, Lichterfeld M.

J Infect Dis. 2014 May 1;209(9):1315-20. doi: 10.1093/infdis/jit628. Epub 2013 Nov 25.

20.

Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.

Puertas MC, Massanella M, Llibre JM, Ballestero M, Buzon MJ, Ouchi D, Esteve A, Boix J, Manzardo C, Miró JM, Gatell JM, Clotet B, Blanco J, Martinez-Picado J; MaraviBoost Collaborative Group.

AIDS. 2014 Jan 28;28(3):325-34. doi: 10.1097/QAD.0000000000000066.

PMID:
24185044
21.

Reactivation of latent HIV-1 in central memory CD4⁺ T cells through TLR-1/2 stimulation.

Novis CL, Archin NM, Buzon MJ, Verdin E, Round JL, Lichterfeld M, Margolis DM, Planelles V, Bosque A.

Retrovirology. 2013 Oct 24;10:119. doi: 10.1186/1742-4690-10-119.

22.

Susceptibility to CD8 T-cell-mediated killing influences the reservoir of latently HIV-1-infected CD4 T cells.

Buzon MJ, Yang Y, Ouyang Z, Sun H, Seiss K, Rogich J, Le Gall S, Pereyra F, Rosenberg ES, Yu XG, Lichterfeld M.

J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):1-9. doi: 10.1097/QAI.0b013e3182a1bc81.

23.

Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy.

Negredo E, Massanella M, Puertas MC, Buzón MJ, Puig J, Pérez-Alvárez N, Pérez-Santiago J, Bonjoch A, Moltó J, Jou A, Echeverría P, Llibre JM, Martínez-Picado J, Clotet B, Blanco J.

J Antimicrob Chemother. 2013 Oct;68(10):2358-62. doi: 10.1093/jac/dkt183. Epub 2013 May 14.

24.

Modelling HIV-1 2-LTR dynamics following raltegravir intensification.

Luo R, Cardozo EF, Piovoso MJ, Wu H, Buzon MJ, Martinez-Picado J, Zurakowski R.

J R Soc Interface. 2013 May 8;10(84):20130186. doi: 10.1098/rsif.2013.0186. Print 2013 Jul 6.

25.

Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification.

Massanella M, Esteve A, Buzón MJ, Llibre JM, Puertas MC, Gatell JM, Domingo P, Stevenson M, Clotet B, Martinez-Picado J, Blanco J; IntegRal Collaborative Group.

J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):152-60. doi: 10.1097/QAI.0b013e318289439a.

PMID:
23392458
26.

Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers.

Pereyra F, Lo J, Triant VA, Wei J, Buzon MJ, Fitch KV, Hwang J, Campbell JH, Burdo TH, Williams KC, Abbara S, Grinspoon SK.

AIDS. 2012 Nov 28;26(18):2409-12. doi: 10.1097/QAD.0b013e32835a9950.

27.

Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery.

Massanella M, Negredo E, Puig J, Puertas MC, Buzón MJ, Pérez-Álvarez N, Carrillo J, Clotet B, Martínez-Picado J, Blanco J.

AIDS. 2012 Nov 28;26(18):2285-93. doi: 10.1097/QAD.0b013e328359f20f.

PMID:
23018435
28.

Novel two-round phenotypic assay for protease inhibitor susceptibility testing of recombinant and primary HIV-1 isolates.

Puertas MC, Buzón MJ, Ballestero M, Van Den Eede P, Clotet B, Prado JG, Martinez-Picado J.

J Clin Microbiol. 2012 Dec;50(12):3909-16. doi: 10.1128/JCM.01636-12. Epub 2012 Sep 26.

29.

HIV-1 capture and antigen presentation by dendritic cells: enhanced viral capture does not correlate with better T cell activation.

Rodriguez-Plata MT, Urrutia A, Cardinaud S, Buzón MJ, Izquierdo-Useros N, Prado JG, Puertas MC, Erkizia I, Coulon PG, Cedeño S, Clotet B, Moris A, Martinez-Picado J.

J Immunol. 2012 Jun 15;188(12):6036-45. doi: 10.4049/jimmunol.1200267. Epub 2012 May 11.

30.

CD4 T-cell regeneration in HIV-1 elite controllers.

Yang Y, Al-Mozaini M, Buzon MJ, Beamon J, Ferrando-Martinez S, Ruiz-Mateos E, Rosenberg ES, Pereyra F, Yu XG, Lichterfeld M.

AIDS. 2012 Mar 27;26(6):701-6. doi: 10.1097/QAD.0b013e3283519b22.

31.

Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.

Llibre JM, Buzón MJ, Massanella M, Esteve A, Dahl V, Puertas MC, Domingo P, Gatell JM, Larrouse M, Gutierrez M, Palmer S, Stevenson M, Blanco J, Martinez-Picado J, Clotet B.

Antivir Ther. 2012;17(2):355-64. doi: 10.3851/IMP1917. Epub 2011 Sep 28.

PMID:
22290239
32.

Deep molecular characterization of HIV-1 dynamics under suppressive HAART.

Buzón MJ, Codoñer FM, Frost SD, Pou C, Puertas MC, Massanella M, Dalmau J, Llibre JM, Stevenson M, Blanco J, Clotet B, Paredes R, Martinez-Picado J.

PLoS Pathog. 2011 Oct;7(10):e1002314. doi: 10.1371/journal.ppat.1002314. Epub 2011 Oct 27.

33.

A non-infectious cell-based phenotypic assay for the assessment of HIV-1 susceptibility to protease inhibitors.

Buzon MJ, Erkizia I, Pou C, Minuesa G, Puertas MC, Esteve A, Castello A, Santos JR, Prado JG, Izquierdo-Useros N, Pattery T, Van Houtte M, Carrasco L, Clotet B, Ruiz L, Martinez-Picado J.

J Antimicrob Chemother. 2012 Jan;67(1):32-8. doi: 10.1093/jac/dkr433. Epub 2011 Oct 12.

PMID:
21994909
34.

Inhibition of HIV-1 integration in ex vivo-infected CD4 T cells from elite controllers.

Buzon MJ, Seiss K, Weiss R, Brass AL, Rosenberg ES, Pereyra F, Yu XG, Lichterfeld M.

J Virol. 2011 Sep;85(18):9646-50. doi: 10.1128/JVI.05327-11. Epub 2011 Jul 6.

35.

Combined antiretroviral therapy and immune pressure lead to in vivo HIV-1 recombination with ancestral viral genomes.

Buzón MJ, Wrin T, Codoñer FM, Dalmau J, Phung P, Bonjoch A, Coakley E, Clotet B, Martinez-Picado J.

J Acquir Immune Defic Syndr. 2011 Jun 1;57(2):109-17. doi: 10.1097/QAI.0b013e318215ab0a.

PMID:
21372727
36.

Transcriptional profiling of CD4 T cells identifies distinct subgroups of HIV-1 elite controllers.

Vigneault F, Woods M, Buzon MJ, Li C, Pereyra F, Crosby SD, Rychert J, Church G, Martinez-Picado J, Rosenberg ES, Telenti A, Yu XG, Lichterfeld M.

J Virol. 2011 Mar;85(6):3015-9. doi: 10.1128/JVI.01846-10. Epub 2010 Dec 22.

37.

Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure.

Codoñer FM, Pou C, Thielen A, García F, Delgado R, Dalmau D, Santos JR, Buzón MJ, Martínez-Picado J, Alvarez-Tejado M, Clotet B, Ruiz L, Paredes R.

Antiviral Res. 2010 Dec;88(3):281-6. doi: 10.1016/j.antiviral.2010.09.016. Epub 2010 Sep 29.

PMID:
20883724
38.

Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers.

Julg B, Pereyra F, Buzón MJ, Piechocka-Trocha A, Clark MJ, Baker BM, Lian J, Miura T, Martinez-Picado J, Addo MM, Walker BD.

Clin Infect Dis. 2010 Jul 15;51(2):233-8. doi: 10.1086/653677.

39.

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

Buzón MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, Gatell JM, Domingo P, Paredes R, Sharkey M, Palmer S, Stevenson M, Clotet B, Blanco J, Martinez-Picado J.

Nat Med. 2010 Apr;16(4):460-5. doi: 10.1038/nm.2111. Epub 2010 Mar 14.

PMID:
20228817
40.

The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.

Buzón MJ, Dalmau J, Puertas MC, Puig J, Clotet B, Martinez-Picado J.

AIDS. 2010 Jan 2;24(1):17-25. doi: 10.1097/QAD.0b013e328331c81e.

PMID:
19770695
41.

Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility.

Puertas MC, Buzón MJ, Artese A, Alcaro S, Menendez-Arias L, Perno CF, Clotet B, Ceccherini-Silberstein F, Martinez-Picado J.

J Virol. 2009 Aug;83(15):7434-9. doi: 10.1128/JVI.00487-09. Epub 2009 May 20.

42.

Transient treatment exclusively containing nucleoside analogue reverse transcriptase inhibitors in highly antiretroviral-experienced patients preserves viral benefit when a fully active therapy was initiated.

Bonjoch A, Buzon MJ, Llibre JM, Negredo E, Puig J, Pérez-Alvarez N, Videla S, Martinez-Picado J, Clotet B.

HIV Clin Trials. 2008 Nov-Dec;9(6):387-98. doi: 10.1310/hct0906-387.

PMID:
19203904
43.

Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection.

Dalmau J, Puertas MC, Azuara M, Mariño A, Frahm N, Mothe B, Izquierdo-Useros N, Buzón MJ, Paredes R, Matas L, Allen TM, Brander C, Rodrigo C, Clotet B, Martinez-Picado J.

Clin Infect Dis. 2009 Jan 15;48(2):229-38. doi: 10.1086/595704.

44.

Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.

Buzón MJ, Marfil S, Puertas MC, Garcia E, Clotet B, Ruiz L, Blanco J, Martinez-Picado J, Cabrera C.

Antivir Ther. 2008;13(7):881-93.

PMID:
19043922

Supplemental Content

Loading ...
Support Center